Good morning, and welcome to the Plexus Corp. Conference Call regarding its Fiscal First Quarter 2024 Earnings Announcement. My name is Livia, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. After a brief discussion by management, we will open the conference call for questions. The conference call is scheduled to last approximately one hour. Please note that this conference call is being recorded. I would now like to turn the call over to Mr. Shawn Harrison, Plexus Vice President of Investor Relations.

Thank you, Livia. Good morning everyone, and thank you for joining us today. Some of the statements made and information provided during our call today will be forward-looking statements, including without limitation, those regarding revenue, gross margin, selling and administrative expense, operating margin, other income and expense, taxes, cash cycle, capital allocation and future business outlook. Forward-looking statements are not guarantees, since there are inherent difficulties in predicting future results and actual results could differ materially from those expressed or implied in the forward-looking statements. For a list of factors that could cause actual results to differ materially from those discussed, please refer to the company's periodic SEC filings, particularly the risk factors in our Form 10-K filing for the fiscal year ended September 30, 2023, and the safe harbor and fair disclosure statement in our press release. We encourage participants on the call this morning to access the live webcast and supporting materials at Plexus' website at www.plexus.com, clicking on Investors at the top of that page. Joining me today are Todd Kelsey, Chief Executive Officer; Steve Frisch, President and Chief Strategy Officer; Pat Jermain, Executive Vice President and Chief Financial Officer; and Oliver Mihm, Executive Vice President and Chief Operating Officer. With today's earnings call, Todd will provide summary comments before turning the call over to Oliver and Pat for further details. Let me now turn the call over to Todd Kelsey. Todd?

Thank you, Shawn. Good morning everyone. Please advance to Slide 3. There were many positives during our fiscal first quarter. These included strong quarterly wins across our market sectors, totaling $261 million, including the addition of two new exciting healthcare life sciences logos. Robust expansion of our funnel of qualified manufacturing opportunities, which now exceeds $4 billion. When combined with a total available market exceeding $240 billion, this supports our expectation of continued industry-leading revenue growth with a targeted CAGR of 9% to 12%. Ongoing advancement of our sustainable and responsible business practices, along with numerous efforts by our team members to help create a better world and positively impact our communities. Yet the quarter had its challenges, primarily associated with further demand softening in the Healthcare/Life Sciences sector and certain subsectors of the industrial market. The resulting revenue decline has created inefficiencies across our organization, which we are addressing as we remain focused on delivering a 5.5% GAAP operating margin in fiscal 2025. These actions will be discussed in more detail later in the call. Please advance to Slide 4 for a review of our fiscal first quarter results. We delivered fiscal first quarter revenue of $983 million, GAAP operating margin of 4.6%, including 54 basis points of stock-based compensation expense, and GAAP EPS of $1.04, including $0.19 of stock-based compensation expense. These results met the updated guidance provided on January 16, 2024, and reflected the impact of significant negative operating leverage as demand weakened late during the fiscal first quarter, limiting our ability to appropriately adjust expenses. Please advance to Slide 5. Our go-to-market organization is leveraging the current environment to create significant opportunities for future growth. We won 30 new manufacturing programs worth $261 million annually when fully ramped into production, led by continued strength from our Healthcare/Life Sciences market sector as well as strong performance from our Industrial market sector. Concurrently, we expanded our funnel of qualified manufacturing opportunities by more than $300 million versus the prior quarter to greater than $4 billion. The funnel increase was highlighted by a large expansion and opportunities in our Aerospace and Defense and Healthcare/Life Sciences market sectors. Our Aerospace and Defense funnel is at an all-time high positioning us for continued strong growth in the sector. Please advance to Slide 6. I'm proud of how our Plexus team continues to innovate and operate to advance our sustainable and responsible business practices. During the quarter, Plexus joined the U.N. Global Compact, a voluntary leadership platform for the development, implementation, and disclosure of socially responsible business practices. Further, we set fiscal 2024 sustainability goals, including an additional 5% energy intensity reduction globally as well as 5% waste intensity reduction. I'd also like to highlight some well-deserved recognition for our team members as they create a better Plexus and a better world positively impacting our communities. The Malaysia chapter of HR Asia selected Plexus as one of the best companies to work for in Asia for a remarkable third time. In addition, they presented Plexus with the HR Asia Diversity, Equity, and Inclusion Award. Plexus was selected by the Fox Cities Chamber of Commerce in Wisconsin as the 2023 Large Company of the Year. Our Neenah operations site hosted more than 80 high schoolers in support of a Smart Girls Rock event that connected mentors from a variety of STEM-related careers, inspiring these students to pursue a career in STEM. And finally, Insight Magazine named Pat Jermain, Wisconsin Public Company CFO of the Year for 2023. Pat, congratulations and thank you for your leadership and commitment to fostering the growth and development of our company and our team. Please advance to Slide 7. For the fiscal second quarter, we continue to see healthy commercial aerospace orders, inclusive of unfulfilled customer demand, slowly rebounding semiconductor capital equipment demand aided by share gains and an ongoing tailwind from new industrial program ramps. However, the near-term demand weakness and inventory corrections from the Healthcare/Life Sciences market sector and certain subsectors of the industrial market are greater than previously anticipated, creating numerous inefficiencies across our business. While the move to outsourcing continues as highlighted by our robust funnel of qualified manufacturing opportunities, we are seeing some slowness in customer decision-making on new product development projects, particularly in the Healthcare/Life Sciences market sector, which is creating challenges for our engineering team. As a result, we are guiding fiscal second-quarter revenue of $930 million to $970 million. Non-GAAP operating margin of 4.0% to 4.4%, inclusive of approximately 72 basis points of stock-based compensation expense, and non-GAAP EPS of $0.80 to $0.95 inclusive of $0.25 of stock-based compensation expense. Our GAAP EPS guidance of $0.48 to $0.63 also includes approximately $10 million or $0.32 of restructuring charges. We expect to complete the associated restructuring actions by our fiscal third quarter and believe they will result in approximately $20 million of annualized cost savings. While we anticipate some cost leverage and margin benefit from these actions during the fiscal second quarter, typical seasonal cost headwinds and other investments, which Pat will discuss later in the call, coupled with our lower revenue forecast will more than offset the immediate benefit. While I continue to challenge our team to deliver $5 billion in annual revenue with a 5.5% GAAP operating margin by our fiscal 2025, the path to $5 billion in that timeframe has become more challenging, given current market dynamics. As a result, we are implementing several strategic actions, leading to the restructuring charge to enable better scalability, create greater efficiency, and align our cost structure to position Plexus for future investments and long-term growth. We are rightsizing in areas where we have excess capacity, which includes personnel reductions. While these actions are necessary to position Plexus for future success, they are incredibly difficult for all of us, given the personal effect on our valued Plexus team members. In addition, we are actively managing discretionary spending, including implementing a temporary salary reduction for our executive leadership team. We understand that we cannot control the demand environment, but we can ensure that we continue to evolve in order to deliver great operational efficiency, supporting the industry-leading returns that our shareholders value and expect. We anticipate the second quarter of fiscal 2024 will represent a revenue trough and are expecting sequential revenue growth with our operating margin expansion of 30 to 50 basis points during each of the fiscal third and fourth quarters. We expect to deliver operating improvements resulting from the restructuring actions, increased manufacturing revenue, and improved utilization within engineering and remain committed to delivering a 5.5% GAAP operating margin in fiscal 2025. Please advance to Slide 8. Finally, as we look forward, I remain confident that Plexus will deliver then exceed $5 billion in annual revenue while also achieving superior returns for our shareholders. We see tremendous runway for continued organic growth in excess of the industry without any substantial shifts to our target market sectors or strategy. Even with some of our markets still recovering post-COVID, we grew revenue at an approximately 8% CAGR during the last five fiscal years ended in 2023. This performance is 250 basis points in excess of the industry and in many cases, more than 2x or 3x the growth rate of our competitors. As detailed on this slide, our market sector leaders estimate there is a greater than $420 billion total addressable market that is directly aligned to the customers and products that fit our strategy and our mission to be the leader in markets featuring highly complex products in demanding regulatory environments. This addressable market is approximately 40% outsourced today, creating a $240 billion opportunity in future outsourcing for Plexus, supporting our 9% to 12% revenue CAGR goal. As an organization, we continue to evolve in order to sustain our success. We are focused on driving efficiencies and creating scale, while accelerating the pace of change. Our talented Plexus team is at the heart of our strategy creating trust with our customers, while delivering customer service excellence and exceptional results. We continue to advance our operations to ensure our organic revenue growth remains well in excess of our peers, in line with our 9% to 12% goal, and that we push to deliver at least 5.5% GAAP operating margin, more consistent and greater free cash generation in the industry-leading returns that our shareholders value and expect. I will now turn the call over to Oliver for additional analysis of the performance of our market sectors.

Thank you, Todd. Good morning. I will begin with a review of the fiscal first quarter performance of each of our market sectors, our expectations for each sector for the fiscal second quarter and some directional sector commentary for fiscal 2024. I will also review the annualized revenue contribution of our wins performance for each market sector in the region, and then provide an overview of our funnel of qualified manufacturing opportunities. Starting with the industrial sector on Slide 9, revenue increased 4% sequentially in the fiscal first quarter. This result was below our expectation of a high-single-digit increase. Softer end market demand across some market sub-sectors contributed to the weaker result. As we start the fiscal second quarter, we are experiencing forecast lightness as customers burned down inventory, most notably within the communications sub-sector offset in part by strength in green energy and an incremental increase in SemiCap. This will result in a low-single-digit decline for the industrial sector for the fiscal second quarter. Industrial market sector had strong wins in the fiscal first quarter of $125 million. Wins were balanced across our sub-sectors including SemiCap. New programs include a follow-on commercial vehicle charging platform that will be produced in our Appleton, Wisconsin facility. We also expanded our portfolio with a newer SemiCap customer to include engagement from the Americas region with a complex mechanical assembly that will be produced in our Guadalajara, Mexico campus; we are now engaged with this customer from all three of our regions. One additional highlight from the quarter is an assessment that our engineering team is performing on a product that our customer is currently designing, called a lifecycle assessment; these high-value add engagements examine and measure the environmental impact of a product throughout its lifecycle. By identifying improvement opportunities early and then helping to solution them, Plexus is able to partner with our customers to create products that build a better world. Looking ahead, we anticipate mid-single-digit revenue growth for our industrial market sector for our fiscal 2024, a result of a continued gradual rebound in SemiCap demand, a tailwind from our support of green energy markets, offset by a greater-than-forecast headwind from a technology transition within the communications market. Please advance to Slide 10. Revenue in our Healthcare/Life Sciences sector was down 15% sequentially for the fiscal first quarter, which was below our expectation of a low-double-digit decrease. Market weakness, inventory corrections, customer design modifications, and supplier issues drove the decline. In the near-term, we see soft demand as our customers continue to decrease inventory levels. The net result is that we anticipate our Healthcare/Life Sciences sector to see a mid-single-digit decrease for the fiscal second quarter. Healthcare/Life Sciences sector wins for the fiscal first quarter totaled $113 million and marked the fourth consecutive quarterly increase. This is also the strongest quarter of wins since the second quarter of fiscal 2022. Our wins included programs with two new customers. We have been awarded the production of a drug delivery device and an aesthetic laser-therapy system. Both products will be produced in our Penang, Malaysia campus. Our fiscal first quarter wins also included a competitive market share gain, due to the exceptional operational performance of our team in Oradea, Romania. Looking at the Healthcare/Life Sciences market sector for fiscal 2024 with some inventory corrections lingering into our second fiscal half and the approximately 5 percentage point growth headwind from the year-over-year reduction of components procured at above historical market prices, we anticipate year-over-year revenue decline in the teens. Advancing to Slide 11, our Aerospace and Defense sector increased 6% sequentially in the fiscal first quarter, strengthening modestly and meeting our expectation of a mid-single-digit increase. While unfulfilled customer demand remains, our supply chain team continues to improve component deliveries to support robust underlying commercial aerospace demand. As we look to the fiscal second quarter, temporary declines due to new customer program ramp delays in defense and space are partially offset by continued robustness within commercial aerospace. As a result, we expect a low-single-digit decline for the Aerospace and Defense sector. Our fiscal first quarter wins for the Aerospace and Defense sector were $23 million. We won two strategic defense programs with the current customer, both of which will be produced in our Boise, Idaho facility. We also won an unmanned aerial program that will be produced in our Penang, Malaysia campus. Lastly, our Neenah, Wisconsin facility won a program that reflects the continuation of multiple awards over the past year for design validation and production work related to its space program, including systems for power management, control, and guidance. For fiscal 2024, Aerospace and Defense demand remains generally robust and is supported by an ongoing backlog. As a result, we expect revenue growth for fiscal 2024 exceeding the high-teens growth witnessed in fiscal 2023. Advancing to Slide 12, we can review the regional highlights of the manufacturing wins for the fiscal first quarter. The Americas wins were robust at $139 million and included the second consecutive quarter with a substantial win from a newer top 10 medical OEM for our Guadalajara, Mexico campus. The APAC region's first fiscal quarter wins at $86 million reflected a marked increase in contribution from the Healthcare/Life Sciences sector with over half of the region's wins from that sector. The region also continued trend of strong wins performance from the industrial sector, including meaningful wins from two of our existing SemiCap customers. The EMEA region's wins first quarter wins of $36 million adds to the $280 million of wins from fiscal 2023, supporting the region's continued robust revenue growth outlook and improved profitability forecast. Please advance to Slide 13 for a review of our funnel of qualified manufacturing opportunities. Despite the strong wins performance, the total funnel increased over $4 billion as all regions saw meaningful increases in their funnel. This $4 billion result is our second largest reported funnel. Given the strength of their wins performance, the industrial sector funnel dipped slightly to $914 million. Aligned with our sector strategy, the opportunities reflected in our funnel are balanced across a variety of markets. Additions to the funnel from both customers and targets in our SemiCap sub-sector helped to backfill the wins. The Healthcare/Life Sciences sector funnel saw a sizable increase to $2.2 billion, more than offsetting the impact of this quarter's strong wins performance. The strength of wins and the increasing funnel of qualified manufacturing opportunities provide optimism for future growth within the Healthcare/Life Sciences sector. The Aerospace and Defense sector grew the funnel to a record high of $923 million, nearly doubling the funnel from Q1 of fiscal 2023. This is supported in part by growth with new targets in addition to growth of opportunities from our current customers. Lastly, the funnel of opportunities for our engineering services saw increases across all market sectors and hit a record high. While there has been delayed decision-making, particularly with our engineering customers in the Healthcare/Life Sciences sector, the funnel strength furthers our optimism for future growth and significantly improved performance. I will now turn the call to Pat for an in-depth review of our financial performance.

Thank you, Oliver, and good morning, everyone. Our fiscal first quarter results, I summarized on Slide 14. With revenue below our original guidance, gross margin of 9% came in slightly lower than expected. Reduced fixed cost leverage and unfavorable mix led to the gross margin result. Selling and administrative expense of $43 million was within our guidance range. As a percentage of revenue, SG&A was 4.4%, which was slightly above expectations given the late-quarter decline in demand. GAAP operating margin of 4.6% was below our original guidance due to the loss of leverage within gross margin and SG&A expenses. Non-operating expenses of $10.3 million were consistent with expectations. GAAP diluted EPS of $1.04 was below the original guidance due to the factors previously mentioned along with a slightly unfavorable tax rate. While we continue to measure our performance against GAAP metrics, next quarter we will begin sharing non-GAAP operating margin and EPS exclusive of stock-based compensation expense for easier comparability to peers. Turning to our cash flow and balance sheet on Slide 15. We used $3 million of cash to support our operations and spent $29 million on capital expenditures, resulting in negative free cash flow of $32 million for the fiscal Q1. This result was favorable to initial expectations as we intentionally delayed a portion of capital spending to more evenly spread-out cash payments throughout fiscal 2024. With the fiscal first quarter typically requiring investments within operations, we did not repurchase any of our stock under the existing authorization. However, as announced last week, our Board approved a new $50 million share repurchase authorization, bringing the total available amount to approximately $56 million. Starting next week, we plan to begin purchasing shares under these authorizations while taking market conditions into consideration. We plan to fund investments in operations and share repurchases with our strong and liquid balance sheet. We ended the fiscal first quarter with a cash balance of $232 million and total debt of $443 million. We had $257 million available to borrow under our credit facility and a conservative gross debt-to-EBITDA ratio of less than 1.7x. For the fiscal first quarter, we delivered a return on invested capital of 10.3%, which was 210 basis points above our weighted-average cost of capital. The cash cycle ended the fiscal first quarter at 95 days, sequentially higher by eight days. Please turn to Slide 16 for details on our cash cycle. The majority of the cash cycle increase came from inventory days primarily due to lower revenue. While days increased by seven, gross inventory dollars were only modestly higher by $13 million compared to the prior quarter and were favorable to expectations. We continue to be encouraged by the work our supply chain and regional teams are doing to drive reduction in inventory while facing challenges with customer forecast reductions in a still constrained component environment. As Todd has already provided the revenue and EPS guidance for the fiscal second quarter, I will review some additional details which are summarized on Slide 17. Fiscal second quarter gross margin is expected to be in the range of 8.8% to 9.2%. At the midpoint, gross margin would be consistent with the first quarter. This quarter gross margin will be burdened approximately 60 basis points by seasonal compensation cost increases and the reset of payroll taxes for U.S. employees. We plan to earn through this margin headwind with productivity improvements across all three of our manufacturing regions along with a portion of savings recognized from our restructuring efforts. We expect selling and administrative expenses in the range of $46.5 million to $47.5 million, which represents a modest increase year-over-year. Sequentially, SG&A is higher primarily due to the seasonal compensation headwinds and investments in essential IT solutions to support our business. Non-operating expenses are anticipated to be in the range of $10.5 million to $11 million, fairly consistent with fiscal first quarter. Our non-GAAP effective tax rate for both the fiscal second quarter and fiscal year is expected to be in the range of 15% to 17%. Our expectation for the balance sheet is that working capital investments will increase slightly compared to the fiscal first quarter. Based on our revenue forecast, we expect this level of working capital will result in cash cycle days in the range of 99 to 103 days. At the midpoint, this would be sequentially higher by six days, primarily due to inventory requirements and anticipated advanced payments returning to customers. With modest working capital investments coupled with our restructuring activities and higher capital spending to support anticipated future revenue growth, we expect the usage of cash for the fiscal second quarter. A few comments on the full year. We have reduced our expected capital spending by $10 million to now be in the range of $100 million to $120 million. We are projecting slightly higher working capital investments compared to the prior year to fund growth expectations in the second half of fiscal 2024. With this said, we believe both gross inventory and advanced payments from customers will be at levels lower than the past two fiscal year ends. Also, we expect to deliver improved free cash flow as we move through fiscal 2024 ending the year with up to $50 million. With that, Livia, let's now open the call for questions.

Our first question comes from David Williams with The Benchmark Company.

So a lot to get through here, but just I guess firstly, if you kind of think about the softness in the Industrial segment, which isn't really surprising. But can you kind of give us a sense of how your customers' tone has been and kind of partly maybe the inventory versus the demand side and how much of this is the burn down versus just a more cautious outlook in the future quarters?

Yes, I'll begin by discussing our various markets and what we are observing, and then I will hand it over to the rest of the team to address inventory in relation to demand. Our markets are quite interesting, showing a rolling progression in strength and weakness post-pandemic and stimulus, which varies significantly by sector. In Aerospace and Defense, which is the furthest along in recovery, we faced many challenges after the pandemic but are currently experiencing a boom phase and strong performance. As Oliver mentioned, we are coming off a year of high-teens growth and anticipate even better results in fiscal '24, driven by a solid pipeline. Turning to the industrial sector, there are several areas to consider, starting with SemiCap. After a sharp decline over a year ago, it's now on a modest upward trend following a low point in Q4 of fiscal '23, largely due to market share gains. However, other industrial markets, particularly communications, are currently facing significant near-term challenges, which we believe to be a temporary situation as new technology is adopted. Lastly, in Healthcare and Life Sciences, we also perceive the current downturn as temporary. However, this sector is experiencing a deeper decline than we have seen historically. Contributing factors include inventory corrections from certain device manufacturers that overestimated demand, as well as the impact of components purchased last year at inflated prices that are returning to normal levels. Additionally, delays in program ramp-ups due to customer design or supplier issues are affecting this market. The differences across markets lead to varied impacts, but the immediate challenges in healthcare and communications are disproportionately influencing our business at the moment. I will now pass it on to...

Sure. I mean specific to the industrial sector, because I think that's where we started, right? We do see some general inventory burden down. But as Todd noted, it's really focused on the communications sub-sector. And as we look across the rest of that sector, there is, I think, signs for optimism. I think we see some incremental improvement here ahead of us in test and measurement. We've got some nice tailwind in green energy, although admittedly that's coming off of a smaller base, but that provides a bit of a tailwind. And then Todd also mentioned our SemiCap sub-sector. One additional data point I will note there is, if we look at our fiscal '24 outlook for SemiCap, that held flat quarter-over-quarter. So, I think another data point that suggests signs for optimism in that sub-sector.

Great. Thanks for the color there. And then maybe secondly on the restructuring, and you think about some of the reductions that you are making. How do you think about that in terms of the second half rebound? And just maybe, if you could walk through some of the changes or the restructurings that you are making, where those are and what we should expect in terms of demand, excuse me, of impact to your capabilities? Thank you.

I want to start, David, by saying that we don't take actions like this lightly, given the impact on our team members and the communities that we are a part of. But we do have, and we have talked about having a playbook to protect our profitability. So we want to ensure that we are positioning ourselves for this 5.5% GAAP operating margin target that we have, and we believe that's what we are doing. So what we're doing is we are taking a look at areas where we can enable better scalability, create greater efficiencies, align our cost structures to position us for future investments. So that primarily involves, I'd call it, rightsizing capacity, and mostly across our operations. It hit manufacturing, services, and engineering. We talked about engineering being light due to healthcare, that's having a pretty substantial drag on our operating margin performance, given the ratio of cost the essence that, the cost within engineering is relatively fixed. So we think we are putting in place opportunities to better position our company for the future as we go forward on this. When we talked about what it does to the second half and the second half rebound, as I mentioned in the prepared scripts, we look at it as being about a $20 million annualized cost savings or about $5 million per quarter. So you can think of it as, once we get these fully implemented and moving forward, somewhere in the order of 50 basis point impact.

First of all, I just wanted to say thanks for giving us a framework for the full-year segment revenue; it's super helpful. So, to start, I've got a quick one for Oliver. I pretty much ask the same question every quarter. Could we get an update on the lead times? Last quarter, I think you noted even though lead times were coming down, they were still running at about twice the normal range. Have we gotten any closer to normalization there?

Yes. Thanks, Melissa. Happy to answer that. So, similar to the message from last quarter, commodities are broadly showing stability. I think when we talked about this last quarter, we said that as you noted just over six months, we've moved from essentially 23 weeks to 22 weeks across our broader commodity base, so just an incremental improvement there. As I reflect on the whole dynamic for us, I'll say that our shortages and the challenge spots are less semiconductor focused. So, a couple of quarters ago that was really just in the semiconductor slice of our supply chain, and now includes an element of passes as well. So, that I view as a further step towards normalization. Within semiconductor, we came from 200 days down to 188 days. So, just running a bit over six months. And then within semiconductor, as we've talked about historically, still see and high-end semiconductor with lagging edge technology, we still see tight inventory and the occasional unexpected decommit and then generally no stock on the open market to help address that.

So, I just wanted to follow up on the last question about the restructuring actions you're taking. Maybe a little bit less delicately. So, Todd, I think you explained that there's some consolidation or optimization across from your facilities. Is there a factor or is there a business you expected to win and had capacity dedicated to it, but now maybe that's no longer an opportunity so you're resizing some of those businesses?

No, there's really none of that, Melissa. It's really more of a softening in markets that we're seeing. No, as we talked about in engineering, we're seeing some delays in decision-making and such, which is causing us to pause there. But when we look at manufacturing or services, it's just general market softening, and it really relates primarily to our Healthcare/Life Sciences market sector.

Just a few questions from me. One, just in terms of top-line and your expectations for sequential growth in the subsequent quarters in the back half of '24. I guess the question is, has your visibility improved or confidence improved given that looking at the last six quarters or so? I think there are at least three quarters where there had been top-line issues or headwinds in the quarter for various reasons, right? So, I guess the question is, has that confidence or visibility improved, and how?

Yes. So, Steve is going to take this question, Matt.

I think as Todd talked about in terms of kind of seeing these rolling changes coming through the different sectors, I think it kind of follows that same philosophy where our confidence in the future forecast varies a bit by sector and sub-sector. So specifically, like Aerospace and Defense, much more confident in what we're seeing from the Aerospace and Defense customers in terms of what their demand looks like as well as our confidence in supply chain. So as Oliver kind of gave a little bit of guidance there, I'd say we have more comfort level there. And we see, as Todd highlighted in the industrial sector, stabilization in the SemiCap market. As we are starting to talk to customers about their back half 2024 forecasted into 2025, gaining confidence that those things will come to reality and basically working with them to make sure we can achieve that. A little bit of volatility like the communication sector, Todd talked about. We have seen a few surprises there, but more focused on technology changes and a little bit of shift there. Obviously, going through this Healthcare/Life Sciences challenge now again, ultimately long-term look very confident. If you look at where the wins are at in the funnel, which is indicative of our customers are really kind of trying to reevaluate what their sourcing strategies are. We did have a few customers come out and announce their plans to close facilities and consolidate for us. That's a good thing. We talked about our funnel increasing. Those larger increases are coming from opportunities like that. So there may be a little bit of volatility here in this quarter in terms of where we are seeing those forecasts, but as we look to the future, we expect those inventory corrections kind of burn through real potential for those sub-sectors to take off.

Steve, in terms of that inventory burn at customers in those sectors you discussed, are you getting, do you have a sense from customers or how long that's going to take? And in terms of like forward orders, are you seeing signs, I don't know it's 8 to 12 weeks out that things are improving?

Yes. We are looking at it customer-by-customer and actually product-by-product, and it does vary. Some products, for example, the things that supported COVID, some of the laboratory test equipment, their inventory levels are a bit higher and will take a little bit longer to burn through. Other things more related to surgical platforms or other related elective procedures, we are feeling more confident those will rebound more quickly. We are going through the analysis kind of product-by-product, and it does vary a bit. But again, our confidence level is it will come back. It's not really a product issue, it's just really more of an inventory problem.

One of the things I'd add to Mike or Matt is that when we look at our outlook for the second half of the year, we are approaching it from a very conservative perspective. However, we have several program ramps that are well underway, which will continue to generate additional revenue in the latter half of the year. We have the supply chain improvements that Oliver mentioned, which align with the unmet demand we still have. So, with this cautious view, we are confident that we will see the sequential improvement I referred to. Additionally, I want to quickly address a related revenue component and correct a statement I previously made. When I discussed our growth rate, I noted that we have an 8% CAGR over the last five fiscal years, which is accurate, but that represents a 250 basis point advantage over the industry average, rather than the '25 I mentioned earlier.

Just on the communication side, could you remind us, like what the sub-sectors or industries, because I know you don't play in mobile networks or base stations anymore, right? It's mostly in other areas.

Yes. It's really broad brand infrastructure that we are talking about there, Matt.

And that weakness, are you seeing across your vendor base or customer base?

Yes. I will note that we are well-represented in that technology space. And so as there is an expected technology upgrade here in the future and so when that does manifest, we're going to enjoy the growth as part of that.

Just a couple of quick questions for Pat, if I can. One, Pat, in terms of your expectations for margin expansion in the back half of '24, and obviously gross margins should expand. But in terms of SG&A, you talked about some near-term expenses, but does that go down in Q3 or because of IT costs and others, is that going to be at those elevated levels? Yes, I think we will see improvement in the percentage as we get to the back half of the year. The dollars, I think will stay relatively consistent, Matt. So, from a percentage standpoint, what I'm guiding Q2 at is about 4.9% of revenue, and that is up from Q1. There's really three main components to that. The seasonal compensation cost increases is about $1.5 million. We've got some higher stock-based compensation based on the roll-off of some prior awards. And then as I mentioned some IT system-related investments and a host of things we're doing there around collaboration tools, cyber security, upgrades to manufacturing systems. So that's driving the dollar increase, and I do think that will stay pretty consistent throughout the rest of the year. But from a percentage standpoint, where we're targeting is around 4.5% of revenue, so some leverage improvement as we see top-line growth in the back half of the year.

First of all, Pat, did you mention that you expect the CapEx to come down for the year than your prior projected?

Yes. Previously we had $110 million to $130 million. So, we brought it down $10 million, and some of that's just because of growth investments that are being delayed a bit. We're being really mindful and prudent about the capital spending this year.

And in terms of the funnel, have you mentioned larger opportunities there coming in? And can you talk about how they relate to previous opportunities?

Yes. So, we are still seeing a larger number of large opportunities in our funnel than we had seen historically.

It's Shawn. Just as maybe a little bit of clarification. When we go head-to-head on a program versus competitors, on average, we're winning two-thirds of the time. And so our win ratio when we go into this qualified funnel of opportunities is quite high, whether that's a small program or one of these larger programs.

And also lastly, the issues that had with some airplanes lately and Boeing having some issues. Is that any risk to you at all or?

Yes. So, the answer from a risk standpoint is no. We do supply Boeing, and we have, I would call it a reasonable, we don't supply Boeing directly, but we do supply into Boeing, and we do have content on the 737 and the 737 MAX. But – and I saw today that the FAA announced that they're going to allow Boeing to go back into production at the rate that they have been at historically, so that would have minimal impact to us. But even if production had been shut down, it'd be of, I'd call it a negligible impact to our overall revenue. So it's pretty insignificant to us.

Thank you. You also mentioned communication seems to be a headwind for you now. But what are you hearing there in terms of the tone and when that could potentially come back?

Yes. I will offer this; as we went into a quarter ago, we thought that that technology upgrade and the bounce back there was going to be early to mid '24. So we are now taking a more conservative view as it being a little bit further out, but the exact timeframe, I hesitate to call the ball for that.

Just wanted to go back to some of the commentary on the market sectors. If we look at where their biggest wildcards are in terms of the improvement that you are anticipating in the fiscal second half. Would you say it's more on the Healthcare/Life Science portion of the business?

I would say, Jim, we are not looking at the markets improving to get the recovery or the growth in revenue that we're projecting. It's more based off of program ramps and activity that's already underway. So any market improvement, whether that comes from healthcare or further increase in SemiCap demand would be upside to what our projections are.

And I guess, Todd, the way of thinking about it is, if there is some potential for negative surprises, where you don't necessarily see progress overall in the second half. Which sector might carry the biggest risk? That's why I was asking the question.

I mean, it would probably have to think about industrial as further degradation of healthcare, but it seems that that's come down a pretty tremendous amount already that it should be at a bottom or close to it.

On the A&D side, it seemed to be suggesting that even with there's been a little bit of it sounds like some program activity slipping on the defense space side, you still seem pretty confident that that shows healthy growth for the year as a whole, with the continued growth that you are seeing in commercial air. Is that fair to say? That is fair to say. Specifically to hit that defense and space headwinds that I mentioned that we are experiencing in Q2, that is a short-term headwind, so that's nothing systemic that we are talking about there. As an example, with one of the program ramps we are doing is actually a bit of a good story here. We were doing printed circuit board assemblies for a customer, and we are performing so well on the ramp and say, 'We want you to do the whole higher-level assembly.' And so we took a pause where we could take over the rest of that business as well. So temporary headwinds, and we do not expect that to persist. Then, as we talked about previously, strong underlying commercial aerospace demand.

One of the things too I'd add, Jim, on our Aerospace and Defense sector, we break it down into four subsectors: Aerospace, Defense, Commercial Space, and Security. And all of them are showing reasonable year-over-year growth in fiscal 2024.

And then finally, you talk about the 5.5% GAAP operating margin in fiscal '25 and that you're committed to protecting that. Does that require if we see in the past, you've talked about $5 billion of revenue? It sounds like you're suggesting you get to those targets even with the restructuring and the cost actions you're doing, even if revenues are not at that level, is that, or am I misinterpreting what you said?

No, I don't think you are, Jim. I mean, what we'd like to get to the $5 billion in revenue, but obviously with current dynamics and the current results and guide that would take a pretty substantial market improvement to be able to do that. But we can control the operating performance and the operating margin. That's part of the reason for us looking at the restructuring actions as well as some other activities is we believe that that's a level of performance that we need to deliver.

No, we don't believe so. I mean, obviously, we'll need to get some additional revenue growth, so we get leverage. It really comes down to the restructuring actions, better utilization within our engineering team and then some manufacturing leverage.

First, I missed this earlier, but I want to say congratulations to Pat on the CFO of the year; it's certainly well-deserved and I think we would all agree to that. So, congratulations there.

Thanks, David.

Yes, of course. And then secondly, just want to ask real quickly on the previous unverified list addition that you guys were trying to clarify. Was there any impact from that and anything longer term we should think about here, any further risk or just any color around that would be helpful I think?

Yes. So, we've been able to recover through, I'd call it a heroic effort from our supply chain team and our APAC team in the region. So, we don't believe there'll be any impact to our fiscal Q2, although it wasn't easy. But what I would say is that the addition to the list wasn't merited, excuse me. It reflected more of a communications issue and a delay in a routine verification of a shipment to our Xiamen facility. The quick removal from the list, which I think was probably like record speed, reflects these facts. So, I would like to call out though the Bureau of Industry and Security within the Department of Commerce and their strong partnership on this to resolve this. So, was very happy with the response that we were able to get. And I'd just like to reiterate, we have a strong compliance program and we remain committed to all laws as well as a strong partnership with the BIAF. So, nothing additional and we're happy that this is behind us.

Nice work getting that cleared quickly. And then just secondly, regionally, it looks like Americas was down quite a bit. Is there anything specific maybe to that area? Is it fair to assume that maybe the more heavily-leveraged to the healthcare industry or anything maybe just around Americas that drove the sequential and year-over-year decline?

Yes. And so I think you have already hit it there, David. I think as we look at the Americas region and the exposure relative to Healthcare/Life Sciences as well as the communication sub-sector is creating that result. And as those sectors come back, we will see the Americas region come back with that.

Thank you. And that concludes the Q&A session. I will now turn the call back over to Mr. Todd Kelsey for any closing remarks.

All right. Thank you, Livia. I'd like to thank our shareholders, investors, analysts, as well as our Plexus team members who joined the call this morning. In closing, I want to say that as I look forward, I remain very confident in our future. And it's our exceptional Plexus team that provides the basis for this view. They continue to differentiate Plexus in the market and with our customers, where we're the leaders in the markets featuring highly complex products and demanding regulatory environments. When we look at this differentiated performance and couple it with the strategically aligned large available markets in which we participate in our commitment to delivering superior operating results, I'm optimistic that we'll continue to outgrow our industry and deliver the strong returns our shareholders expect. Thank you all, and have a great day.

Ladies and gentlemen, that does conclude the conference for today. Thank you for your participation. You may now disconnect.